Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents

Table 4

Ocular adverse events.

	Group 1	Group 2	value
Mean initial IOP	14.2 mmHg	14.1 mmHg	0.93
Mean final IOP	14.1 mmHg	16.5 mmHg	0.0005
Increase > 10 mmHg from baseline	5 (3.3%)	9 (21.4%)	0.0005
Initiation of IOP-lowering medication at any visit	4 (2.7%)	8 (19.0%)	0.0008
Glaucoma surgery	0	3 (7.1%)	0.015
Cataract surgery	6 (4.7%)	12 (36.3%)	0.0009